Importantly, targeting oxidative stress regulators—such as inhibiting NQO1 or ATF4 in MSS tumors, or modulating MAPK3 and ROS balance in MSI tumors—may provide opportunities for tailored therapeutic strategies to enhance 5-FU efficacy in a subtype-specific manner. The gene discussed is MAPK3; the disease is Marinesco-Sjogren syndrome.